Jacobs & Co. CA Has $433,000 Stock Holdings in Baxter International Inc. (NYSE:BAX)

Jacobs & Co. CA cut its holdings in Baxter International Inc. (NYSE:BAX) by 36.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,219 shares of the medical instruments supplier’s stock after selling 6,412 shares during the quarter. Jacobs & Co. CA’s holdings in Baxter International were worth $433,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Headinvest LLC acquired a new stake in shares of Baxter International in the third quarter worth $25,000. Indiana Trust & Investment Management CO acquired a new stake in shares of Baxter International in the third quarter worth $27,000. Bruce G. Allen Investments LLC bought a new position in Baxter International during the fourth quarter worth $36,000. BKM Wealth Management LLC bought a new position in Baxter International during the fourth quarter worth $44,000. Finally, Farther Finance Advisors LLC increased its position in Baxter International by 28.5% during the second quarter. Farther Finance Advisors LLC now owns 1,185 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 263 shares during the period. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BAX. JPMorgan Chase & Co. boosted their target price on shares of Baxter International from $38.00 to $44.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. UBS Group lowered their price target on shares of Baxter International from $40.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 6th. Bank of America boosted their price target on shares of Baxter International from $42.00 to $45.00 and gave the company a “neutral” rating in a report on Tuesday, March 5th. StockNews.com raised shares of Baxter International from a “hold” rating to a “buy” rating in a report on Friday, January 19th. Finally, Barclays upped their target price on shares of Baxter International from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Monday, February 12th. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $46.18.

Baxter International Price Performance

NYSE BAX opened at $42.69 on Thursday. The stock has a market cap of $21.68 billion, a price-to-earnings ratio of 8.18, a PEG ratio of 2.23 and a beta of 0.62. Baxter International Inc. has a 52-week low of $31.01 and a 52-week high of $50.21. The business has a 50 day simple moving average of $40.81 and a 200 day simple moving average of $37.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.04 and a current ratio of 1.48.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.02. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.81 billion. Baxter International had a net margin of 17.77% and a return on equity of 19.49%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the business earned $0.88 EPS. Analysts anticipate that Baxter International Inc. will post 2.89 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 1st. Stockholders of record on Friday, March 1st will be paid a dividend of $0.29 per share. The ex-dividend date of this dividend is Thursday, February 29th. This represents a $1.16 annualized dividend and a dividend yield of 2.72%. Baxter International’s dividend payout ratio is currently 22.22%.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.